| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.05(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
| 52
Week Range: |
$120.4 - $292.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kovner Bruce |
Director |
– • • |
2012-12-12 |
4 |
A |
$8.60 |
$19,999,997 |
I/I |
2,325,581 |
3,273,281 |
|
- |
|
| Singh Amar |
Sr. VP, Chief Business Officer |
• – – |
2012-11-29 |
4 |
D |
$8.21 |
$32,585 |
D/D |
(3,969) |
21,031 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-11-14 |
4 |
B |
$6.95 |
$73,009 |
I/I |
10,500 |
947,700 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2012-11-12 |
4 |
B |
$6.89 |
$187,449 |
I/I |
27,200 |
937,200 |
2.25 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2012-11-12 |
4 |
B |
$7.12 |
$71,200 |
D/D |
10,000 |
2,373,135 |
2.81 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2012-09-26 |
5 |
GA |
$0.00 |
$0 |
I/I |
59,400 |
65,000 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2012-07-25 |
4 |
A |
$6.49 |
$649,000 |
D/D |
100,000 |
631,539 |
|
- |
|
| Kufe Donald W |
Director |
– • – |
2012-07-25 |
4 |
A |
$6.49 |
$29,997 |
D/D |
4,622 |
11,934 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-07-25 |
4 |
A |
$6.49 |
$19,999,999 |
D/D |
3,081,664 |
8,006,852 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2012-07-25 |
4 |
A |
$6.49 |
$5,000,000 |
I/I |
770,416 |
2,598,383 |
|
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2012-07-25 |
4 |
A |
$6.49 |
$129,800 |
D/D |
20,000 |
2,363,135 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2012-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
14,624 |
202,005 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2012-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,140 |
531,539 |
|
- |
|
| Kufe Donald W |
Director |
– • – |
2012-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,312 |
7,312 |
|
- |
|
| Reardon William S |
Director |
– • – |
2012-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,027 |
19,228 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,140 |
4,925,188 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-06-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,900,000 |
475,000 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-06-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,900,000 |
4,916,048 |
|
- |
|
| Kovner Bruce |
Director |
– • • |
2012-06-29 |
4 |
B |
$5.45 |
$4,959,318 |
D/D |
910,000 |
6,816,048 |
3.92 |
- |
|
| Gollust Keith R |
Director |
– • – |
2012-06-29 |
4 |
B |
$5.35 |
$801,900 |
I/I |
150,000 |
1,827,967 |
2.1 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2012-06-29 |
4 |
B |
$5.34 |
$53,370 |
D/D |
10,000 |
2,343,135 |
2.81 |
- |
|
| Vukovic Vojo |
SVP, Chief Medical Officer |
• – – |
2012-06-29 |
4 |
B |
$5.59 |
$16,755 |
D/D |
3,000 |
25,249 |
2.74 |
- |
|
| Rieder Wendy E |
VP, IP and Legal, Gen. Counsel |
• – – |
2012-06-18 |
4 |
AS |
$6.00 |
$43,020 |
D/D |
(7,170) |
19,823 |
|
- |
|
| Rieder Wendy E |
VP, IP and Legal, Gen. Counsel |
• – – |
2012-06-18 |
4 |
OE |
$2.49 |
$17,853 |
D/D |
7,170 |
26,993 |
|
- |
|
| Rieder Wendy E |
VP, IP and Legal, Gen. Counsel |
• – – |
2012-06-04 |
4 |
AS |
$5.50 |
$39,435 |
D/D |
(7,170) |
19,823 |
|
- |
|
413 Records found
|
|
Page 10 of 17 |
|
|
1.67 (0.81%) 
